Heme

Advertisement
Andrew MorenoMyelofibrosis | May 30, 2025
MANIFEST-2 compares pelabresib plus ruxolitinib with placebo plus ruxolitinib for JAK-inhibitor-naive disease.
Melissa BadamoTTP | May 30, 2025
In a phase 3 study, patients who received recombinant ADAMTS13 did not experience acute TTP events during prophylaxis.
Melissa BadamoAnemia | May 29, 2025
Iron deficiency anemia was associated with 39% increased odds of stroke, independent of the risk factors for stroke.
Melissa BadamoEssential Thrombocythemia | May 27, 2025
While cytoreductive drugs did not reduce thrombosis risk, interferon significantly improved myelofibrosis-free survival.
Andrew MorenoHemophilia | May 20, 2025
A preclinical mouse study showed hemostasis restoration, as well as use for active bleeding and internal bleeding prevention.
Andrew MorenoPNH | May 19, 2025
A novel complement-targeting agent shows impressive efficacy and safety without immunosuppression of the classical pathway.
Andrew MorenoVTE | May 16, 2025
Investigation of a HUNT Study cohort found elevated plasma MBL levels to be associated with increased risk for future VTE.
Andrew MorenoAnemia | May 16, 2025
Reactive oxygen species levels decreased and patients with evident bone marrow failure showed hematological response.
Andrew MorenoVTE | May 19, 2025
A cohort study of extended-phase anticoagulation following acute management was performed in the phase III EINSTEIN Jr trial.
Melissa BadamoHemophilia | May 13, 2025
Fidanacogene elaparvovec gene therapy is a safe and effective treatment for patients with hemophilia B, research shows.
Andrew MorenoPolycythemia Vera | May 12, 2025
The agent targets abnormal gene expression in order to control the excessive cell proliferation that occurs in PV.
Andrew MorenoMDS | May 12, 2025
A study has explored the clinical impact of both mutation-based and non-mutation-based p53 dysfunction in MDS.
Andrew MorenoMDS | May 9, 2025
Preclinical models show significant efficacy in combos against AML cell lines with FLT3, KMT2A, NPM1, and TP53 mutations.
Melissa BadamoSickle Cell Disease | May 7, 2025
Compared with placebo, crizanlizumab has superior safety and comparable efficacy in patients with sickle cell disease.
Andrew MorenoHematology | May 7, 2025
Investigators used two AI-driven tools to analyze multiple myeloma therapies' clinical literature and patent information.
Melissa BadamoMDS | May 6, 2025
Mice treated with the novel approach had a “significantly lower tumor burden” compared with mice that received controls.
Andrew MorenoHematology | May 5, 2025
The two specific combinations recently approved by the MHRA in the UK also have a BLA currently under review at the FDA.
Andrew MorenoHematology | May 5, 2025
The agent produced favorable safety results, had no dose-limiting toxicities, and did not interfere with CAR T-cell therapy.
Paul George, MD, PhDSickle Cell Disease | May 8, 2025
The study led by Paul George, MD, PhD, also highlights the importance of patient regimen adherence to secure these benefits.
Andrew MorenoHemophilia | April 30, 2025
Approval was based on data from phase 3 studies in the ongoing ATLAS clinical development program.
Advertisement